Nanoliposomal irinotecan
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | DRUG-NAL-IRI |
|---|---|
| Tipo | Fármaco |
| Alegais | Irinotecan liposomeOnivydeIR-Nalpegylated liposomal irinotecan |
| Estado | revisto 2026-05-07 |
| Doenças | DIS-PDAC |
| Fontes | SRC-ESMO-PANCREATIC-2024 SRC-NAPOLI1-WANG-GILLAM-2016 SRC-NCCN-PANCREATIC-2025 |
Fatos sobre as drogas
| Classe | Inibidor da topoisomerase I lipossómica |
|---|---|
| Mecanismo | Liposomal irinotecan formulation that delivers irinotecan, a prodrug converted to SN-38, which inhibits topoisomerase I and causes replication- associated DNA damage. |
| Dose típica | Post-gemcitabine metastatic pancreatic adenocarcinoma: 70 mg/m2 free base IV over 90 minutes every 2 weeks with leucovorin and 46-hour infusional fluorouracil. Dose adjust for toxicity and relevant pharmacogenomic risk. |
| Ucrânia registada | Falso |
| NSZU reembolsado | Falso |
Avisos
- Neutropenia grave
- Diarreia grave
Notas
Thin drug entity added to resolve REG-NAL-IRI-5FU-LV-PDAC component references. Do not treat as interchangeable with conventional irinotecan.
Usado por
Esquema terapêutico
REG-NAL-IRI-5FU-LV-PDAC- Nal...IRI + 5-FU/LV (PDAC, 2L nanoliposomal irinotecan)